Shots:
- GlycoNex has reported a licensing agreement to develop SPD8, a biosimilar version of Amgen’s Prolia and Xgeva (denosumab)
- The licensee will secure rights for the development, regulatory activities & commercialization of SPD8 in the designated regions. The deal includes development and commercial milestones, supporting GlycoNex’s global business operations
- SPD8 is under P-III clinical evaluation initiated in Dec 2024 after P-I confirmed its safety and PK equivalence for treating osteoporosis and skeletal-related events in patients with bone metastases from solid tumors
Ref: GlycoNex | Image: GlycoNex
Related News:- GlycoNex Reports the Completion of P-I Study Assessing SPD8 (Biosimilar, Prolia) for Osteoporosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
